IW 1973

Drug Profile

IW 1973

Alternative Names: IW1973; sGC agonist-Ironwood

Latest Information Update: 27 Feb 2017

Price : $50

At a glance

  • Originator Ironwood Pharmaceuticals
  • Class Cardiovascular therapies
  • Mechanism of Action Soluble guanylyl cyclase agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cardiovascular disorders; Hypertension in diabetes
  • Phase I Pulmonary arterial hypertension

Most Recent Events

  • 21 Feb 2017 Phase-II clinical trials in Hypertension in diabetes in USA (PO)
  • 21 Feb 2017 Ironwood initiates a phase IIa trial for Hypertension in diabetes in USA
  • 08 Jan 2017 Ironwood Pharmaceuticals plans phase II trials for Diabetic nephropathies, Resistant hypertension and Heart failure
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top